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Abstract
The capacity to develop protective immunity against mycobacteria is heterogeneously distributed 
among human beings, and it is currently unknown why the initial immune response induced 
against Mycobacterium tuberculosis (Mtb) does not provide proper clearance of this pathogen. 
Dendritic cells (DCs) are some of the first cells to interact with Mtb and they play an essential role 
in development of protective immunity against Mtb. Given that Mtb-infected macrophages have 
difficulties in degrading Mtb, they need help from IFN-γ-producing CD4+ T cells propagated via 
IL-12p70-producing DCs. Here we report that Mtb modifies human DC plasticity by expanding a 
CD14+ DC subset with weak IL-12p70-producing capacity. The CD14+ Mtb-promoted subset was 
furthermore poor inducers of IFN-γ by naive CD4+ T cells, but instead prompted IL-17A-producing 
RORγT+ CD4+ T cells. Mtb-derived peptidoglycan and mannosylated lipoarabinomannan partly 
recapitulated the subset partition induced by Mtb. Addition of IFN-γ, but neither IL-17A nor IL-22, 
which are potentially produced by Mtb-exposed γ/δ-T cells in mucosal linings, inhibited the 
differentiation toward CD14+ DCs and promoted high-level IL-12p70 in Mtb-challenged DCs. We 
conclude that Mtb exploits DC plasticity to reduce production of IL-12p70, and that this process is 
entirely divertible by exogenous IFN-γ. These data suggest that strategies to increase local IFN-γ 
production in the lungs of tuberculosis patients may boost host immunity toward Mtb.
Keywords: co-stimulatory molecules, IL-17, mannosylated lipoarabinomannan, monocytes, naive CD4 T cells
Introduction
Mycobacterium tuberculosis (Mtb) is spread through aero-
sols and enters the body through the lungs (1). Characteristic 
for the immune response against Mtb is the development of 
a granuloma in the lungs, consisting of an aggregate of vari-
ous lymphocytes (2). This limits bacterial spread, but also 
limits interaction of immune cells with infected cells after the 
granuloma has formed. Therefore, the early immune response 
against Mtb is of vital importance to whether the infection will 
be cleared, or a latent infection will manifest. Obviously, the 
number of people able to naturally resist Mtb infection is not 
known, but with one-third of the world’s population currently 
infected (3), clearly many people do not develop a proper early 
immune response against Mtb being able to clear the infection.
The first cells Mtb interacts with are considered to be 
alveolar macrophages and myeloid dendritic cells (DCs) 
(4–6). Normally when micro-organisms are taken up by 
macrophages they are degraded in the lysosomal compart-
ment (7, 8). Mtb, however, has developed a technique to 
divert this by inhibiting fusion of the phagosomes with the 
lysosomes, and by inhibiting autophagy (9). Consequently, 
Mtb resides as an intracellular microbe surviving within 
lung-resident macrophages. Clearance of this type of 
pathogen most essentially requires a CD4+ Th1 immune 
response, which is needed to activate the phagolysosomal 
process in infected macrophages in an antigen-specific 
manner, and further to provide help for CD8+ cytotoxic 
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T lymphocytes capable of killing infected cells (10–13). 
Because DCs are the only cells capable of activating naive 
CD4+ T cells, the DC response to Mtb is considered a criti-
cal factor for how the immune response to Mtb evolves. 
Unlike inside macrophages, Mtb is not able to grow inside 
DCs (14). Upon uptake of Mtb, DCs migrate to the draining 
lymph nodes (4, 6). Here they interact with naive T cells, 
presenting Mtb-derived antigen and providing co-stimula-
tory and differentiation signals for the T cells (15). After 
activation, T cells migrate back to the infection site, where 
they help control the infection (1). However, currently little 
is known about the phenotype of the T cells present at the 
site of infection at early stages.
DC-produced IL-12p70 is necessary for induction of a 
Th1 response (16, 17), which is enhanced by IL-27 (18, 19). 
IL-1β, IL-6 and IL-23 are important for expansion of human 
Th17 cells (20–23) that function to recruit neutrophils via 
IL-17 secretion. However, the role of Th17 cells during an Mtb 
infection in humans has not yet been elucidated (24). IL-10 
acts as a general immunosuppressive cytokine, and the 
cytokine plays a specific role during Mtb infection by inhibit-
ing autophagy (25, 26). The remarkable functional plasticity 
of DCs to induce these different types of responses depends 
on which signals the DCs receive from the environment (27). 
For example, activation of toll-like receptor (TLR)2 or nucle-
otide oligomerization domain (NOD) 2 in monocyte-derived 
DCs (moDCs) gives rise to very low levels of IL-12p70, while 
a combined activation of the two pattern recognition recep-
tors (PRRs) results in intermediate amounts of IL-12p70 (28). 
Stimulation of TLR4 gives even higher amounts of IL-12p70 
(29), while simultaneous triggering of C-type lectin receptors 
(CLRs) DC-specific intercellular adhesion molecule-3-grab-
bing non-integrin (DC-SIGN, CD209) and the mannose 
receptor (MR, CD206) inhibits TLR4-mediated IL-12p70 pro-
duction, perhaps via increased IL-10 production (30, 31). It 
is well established that Mtb contains ligands for both TLR2 
and NOD2 through its display of lipoproteins and muramyl 
dipeptide, but it has also been suggested that Mtb contains 
non-canonical ligands for TLR4 (32–34). Furthermore, Mtb 
contains genomic DNA that can signal through intracellular 
DNA sensors, TLR9 and stimulator of IFN genes (STING), to 
induce type I IFNs (35, 36) which have been shown to boost 
IL-12p70 production in an autocrine manner (37). Based on 
this insight it is therefore curious that Mtb only induces very 
small, almost undetectable amounts of IL-12p70 in moDCs 
(28, 38–40).
Since the discovery of moDCs, they have been described 
as being CD14-low/negative (41), and CD14 is mainly con-
sidered a monocytic marker. However, CD14+ DCs do exist 
in vivo in the skin (42, 43). These CD14+ dermal DCs have 
been described as having a tolerogenic character, e.g. by 
promoting generation of Tregs (44). The tolerance-induc-
ing compound vitamin D3 has furthermore been shown to 
induce up-regulation of CD14 on otherwise CD14-neg DCs 
(44, 45).
Here we assayed how the phenotype of Mtb-stimulated 
moDCs diverges from a classical Th1-promoting DC subset 
and identify up-regulation of CD14 as one of the major differ-
ences between the two DC phenotypes. The up-regulation 
of CD14 on moDCs was partly recapitulated by a combined 
stimulation with Mtb-derived peptidoglycan (PGN) and man-
nosylated lipoarabinomannan (ManLAM), and in addition to 
a diminished induction of a Th1 response, the Mtb-expanded 
CD14+ moDCs also increased the propagation of Th17 A cells. 
Finally, we provide data showing how IFN-γ, but not IL-17A or 
IL-22, can abrogate Mtb-propagated CD14+ development.
Methods
Reagents
The following reagents were obtained through the NIH 
Biodefense and Emerging Infections Research Resources 
Repository, NIAID, NIH: γ-irradiated whole cells from Mtb 
strain H37Rv (NR-14819), purified PGN from Mtb H37Rv (NR-
14853) and purified ManLAM from Mtb H37Rv (NR-14848). 
Escherichia coli LPS (O26:B6) was purchased from Sigma-
Aldrich. Recombinant human IFN-γ (cat. # 285-IF), IL-17A 
(317-ILB) and IL-22 (782-IL) were purchased from R & D 
Systems. The following anti-human antibodies were used in 
the studies: CD1a/PE (clone# HI149), HLA-DR/v500 (G46-6), 
CD86/v450 (2331(FUN-1)), PD-L1/PE-Cy7 (M1H1), DC-SIGN/
FITC (DCN46), MR/APC (19.2) (all from BD Biosciences), 
CD14/PE-Cy7 (61D3), CD45RA/APC (HI100) (all from eBio-
science), CD16/FITC (3G8), CD40/PerCP-Cy5.5 (5C3) (both 
from Biolegend) and CD4/ECD (SFCI12T4D11) (Beckman 
Coulter).
Human blood samples
Human buffy coats were acquired from the blood bank at the 
National Hospital of Denmark (Rigshospitalet) collected from 
anonymous healthy donors. Blood samples were handled in 
accordance with guidelines put forward in the ‘Transfusion 
Medicine Standards’ by the Danish Society for Clinical 
Immunology (www.dski.dk). The buffy coats were obtained 
from 450 ml whole blood donations in citrate phosphate dex-
trose anticoagulant. Whole blood was fractionated to sepa-
rate the majority of erythrocytes and plasma. The buffy coat 
contains ~90% of the leukocytes from the 450 ml of blood and 
was used within 5.5 h upon blood draw.
Cell purification and culture
PBMCs were isolated from human buffy coats by Ficoll-
Paque (GE Healthcare) density centrifugation. The PBMCs 
were labeled with magnetic particle-linked CD14 antibodies 
and isolated using MACS (Miltenyi). Cells were cultured in 
RPMI 1640 (Lonza) containing 2% (volume to volume) l-glu-
tamine (Lonza), 10% fetal bovine serum (FBS; Lonza), 1% 
penicillin, streptomycin (Lonza), 50  µM β-mercaptoethanol 
(Sigma-Aldrich) and 10 mM HEPES (Lonza). Cells were kept 
in a humidified 37°C, 5% CO2 incubator. For differentiation 
of monocytes into immature DCs, the medium was supplied 
with 20 ng ml−1 (≥160 U ml−1) recombinant human GM-CSF 
and 30 ng ml−1 (≥150 U ml−1) recombinant human IL-4 (both 
CellGenix). The cells were grown in polystyrene 6-well plates 
(Nunc) at a concentration of 2 × 106 ml−1. Monocyte cultures 
were supplied with fresh medium containing fresh GM-CSF 
and IL-4 on day 3, and non-adherent immature DCs were har-
vested on day 6. In some experiments CD1a-hi moDCs were 
enriched by MACS as described (46). The purity of CD1a-hi 
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moDCs were >92% for all donors. Immature DCs were plated 
at a cell concentration of 106 ml−1 and stimulated with 500 ng 
ml−1 LPS, 10 µg ml−1 PGN, 50 µg ml−1 ManLAM and 500 µg 
ml−1 Mtb (final concentrations). The concentration of Mtb was 
determined in dose–response experiments (Supplementary 
Figure E1, available at International Immunology Online). 
Right before adding Mtb, clumps of bacteria were disrupted 
through syringe shearing by passing the solution 10 times 
through continuously smaller needles in the order 18-, 21-, 
23-, 25- and 27-gauge. Recombinant human IFN-γ, IL-17A 
and IL-22 was added at 100 ng ml−1.
ELISA
ELISA was performed according to the manufacturer’s 
instructions. Supernatants of stimulated and unstimulated 
DCs were harvested after 24 h and kept at −40°C until analy-
sis. The following ELISA kits were used in this study: human 
IL-1β, IL-6, IL-10, IL-12p70, IL-27, IFN-γ (all R&D Systems) 
and IL-23p19p40 (eBioscience).
Flow cytometry
Flow cytometry was performed according to standard pro-
cedures. The wash and staining buffer consisted of PBS with 
1% FBS and 0.1% Na-azide (Sigma-Aldrich). Before stain-
ing, the cells were incubated for 10 min in staining buffer 
with 2% allogeneic human AB plasma (Rigshospitalet) to 
limit non-specific binding of antibodies. Monocytes were 
analyzed right after isolation, immature moDCs were ana-
lyzed right after harvesting, and stimulated/unstimulated 
moDCs were analyzed after 24 h. FMO (fluorescence minus 
one) controls were tested for all antibody combinations 
and found to be lower or identical to negative control cells 
(monocytes for HLA-DR, CD86, CD40, PD-L1, DC-SIGN 
and MR; and LPS-stimulated moDCs for CD14). Dead 
cells were stained with a near infrared necrotic cell marker 
(Invitrogen) according to the manufacturer’s instructions. 
The dye reacts with amines exposed in cells with a compro-
mised cell membrane.
CD4+ naive T-cell co-culture
PBMCs were enriched for CD3+ cells by Dynabeads FlowComp 
human CD3-kit (Invitrogen), which enables removal of mag-
netically labeled antibodies before cell sorting. CD3-enriched 
PBMCs were labeled with antibodies against CD4/ECD and 
CD45RA/APC and sorted on MoFlo XDP (Beckman Coulter) 
according to CD4+CD45RA++. Purity of T cells were assayed 
on FACSCanto II and were >97% for all donors. Prior to the co-
culture moDCs were stimulated with the respective stimuli for 
6 h. moDCs were washed, counted and added in a ratio of 1:20 
to naive T cells. T cells and moDCs were co-cultured for 6 days. 
Supernatants were harvested, and T cells were re-stimulated 
with 10 ng ml−1 phorbol myristate acetate (PMA; Sigma-Aldrich) 
and 1 µg ml−1 ionomycin (Sigma-Aldrich) for 6 h. After 1 h 10 µg 
ml−1 brefeldin A (BD Biosciences) was added.
Statistics
All data were tested for a Gaussian distribution using a 
D’Agostino and Pearson omnibus test. Data that did not follow 
a Gaussian distribution were either log-transformed or ana-
lyzed by a non-parametric statistical method. When compar-
ing two samples, the Student’s paired t-test or the Wilcoxon 
matched-pairs signed-rank test was used. When comparing 
more than two samples an analysis of variance (ANOVA) or 
the Kruskal–Wallis test was used. All correlation analyses 
are based on Pearson or Spearman correlations. Prism 5 
(Graphpad Software) was used to conduct the analyses.
Results
Mtb induces a IL-12p70-low, CD14+ moDC phenotype
To examine how the phenotype of Mtb-activated moDCs 
diverges from a classical Th1-promoting phenotype, we 
compared the Mtb-induced response pattern to moDCs 
stimulated with a prototypic IL-12p70-inducing ligand; LPS 
derived from E. coli (Fig. 1). LPS induced significantly higher 
levels of especially IL-12p70 but also IL-27 compared with 
Mtb, while Mtb induced higher levels of IL-1β and IL-23 than 
seen for LPS-treated moDCs (Fig. 1A). No difference in IL-6 
and IL-10 production was observed for the two stimuli. To 
study if these results were associated with differences in 
surface marker expression, we compared the expression 
levels of a range of surface markers between Mtb- and 
LPS-stimulated moDCs (Fig. 1B and C). No difference was 
observed for the antigen-presenting molecule HLA-DR nor 
for the co-inhibitory receptor PD-L1, while minor differences 
were found in the expression levels for the co-stimulatory 
molecules CD40 and CD86 as well as the CLRs DC-SIGN 
and MR. However, a large difference in CD14 expression 
was evident for the LPS- and Mtb-activated moDCs. On 
average, a 32-fold induction of CD14 by Mtb relative to LPS 
was seen, which was due to a subpopulation of moDCs that 
dramatically increased CD14 expression after Mtb stimula-
tion (Fig. 1B). As IL-4 has previously been reported to be 
responsible for down-regulation of CD14 (47) and was left 
out of the medium during culture with LPS and Mtb to avoid 
a non-physiological bias of our results, we also investigated 
the phenotype of moDCs left unstimulated for 24 h to deter-
mine the baseline level of CD14 shifting. While the unstimu-
lated moDCs up-regulated CD14 compared with immature 
moDCs, their average CD14 expression was still 8-fold 
less than that observed for Mtb-activated moDCs. Notably, 
the expression level of CD14 on the CD14+ moDC subset 
induced by Mtb was even higher than the CD14 expres-
sion on undifferentiated monocytes (Fig.  1B). Importantly, 
the stimulation of the moDCs with Mtb did not reduce the 
viability of these cells compared with unstimulated or LPS-
stimulated moDCs (Fig. 1D).
Mtb-specific CD14+ moDCs are mainly CD16-neg
CD14 is classically used as a marker of monocytes along 
with the Fcγ receptor III, also known as CD16. To fur-
ther examine the division of Mtb-challenged moDCs into 
a CD14-neg and a CD14+ subset, we assayed CD14 and 
CD16 expression profiles (Fig. 2A and B). Monocytes phe-
notyped immediately after isolation clearly displayed two 
populations with a predominant CD14+CD16-neg popula-
tion and a minor CD14+CD16+ subset, as is routinely seen 
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Fig. 1. Comparison of response pattern between LPS- and Mtb-activated DCs. MoDCs were stimulated with Mtb, LPS or left unstimulated for 
24 h. Secreted cytokines were assayed by ELISA (A) and surface marker expression and viability was determined by flow cytometry (B–D). Data 
on monocytes harvested before DC differentiation, and immature DCs harvested at day 6 of differentiation are also displayed in the histograms 
(C). Each dot in the plots in A represents one donor. (B) Displays a representative donor from the data summarized in C. Error bars represent 
standard deviation, and LPS versus Mtb or versus unstimulated cells were tested for statistically significant differences using either the Student’s 
two-tailed paired t-test or a Wilcoxon matched-pairs signed-rank test (comparing LPS versus Mtb), or an ANOVA with Tukey’s post-hoc test 
(comparing all three conditions). n = 6–21, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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for human monocytes. Immature moDCs had lost most 
CD14 expression while maintaining some degree of CD16 
expression. Upon Mtb stimulation, one-third of the moDCs 
up-regulated CD14; with the CD16+ fraction being CD14+, 
while LPS stimulation lead to almost a complete removal of 
CD16. As shown in Fig.  1, unstimulated moDCs also up-
regulated CD14, but using CD16 as an additional marker 
showed that the CD14+CD16-neg subset made up a signifi-
cantly larger fraction among Mtb-stimulated moDCs than for 
unstimulated moDCs (Fig. 2B). The other three CD14/CD16 
populations did not show a significant difference between 
Mtb-stimulated and unstimulated moDCs, but even though 
the CD14+CD16+ population size was similar on an average 
basis, the mean fluorescence intensity of CD14 was consist-
ently higher for the Mtb-induced cells than for unstimulated 
moDCs (Figs 1C and 2A).
Of notice, moDCs from 2 out of 10 donors assayed did not 
exhibit this ‘plastic’ Mtb-imposed shift in CD14-CD16 dis-
play but instead showed a CD14-CD16 expression pattern 
similar to that observed for LPS-treated cells (data shown 
are only for ‘plastic’ donors). MoDCs from these donors 
were not able to up-regulate CD14 in response to Mtb nor 
when left unstimulated and may reflect the heterogeneity 
of the human population, as previously described by our 
group (46).
Mtb-propagated CD14+ moDCs promote induction of a 
Th17 response rather than Th1 induction
After showing that Mtb exposure propagated a CD14+ moDC 
subset, we speculated whether this subset was associated 
with a differential cytokine production. Therefore, the percent-
age of Mtb-induced CD14+ moDC subset were correlated with 
the cytokine secretion from Mtb-challenged moDCs per indi-
vidual blood donor (Fig. 3A). The data showed a clear inverse 
correlation between %CD14+ moDCs induced by Mtb and 
the level of IL-12 family cytokines (IL-12p70, IL-23 and IL-27) 
and IL-1β. Production of IL-6 and IL-10, however, showed 
no correlation with the Mtb-induced regulation of moDC 
subsets (Fig. 3A). In line with the pattern of moDC cytokine 
production, the %CD14+ moDCs was significantly inversely 
correlated with the level of IFN-γ produced by CD4+ naive 
allogenic T cells co-cultured with Mtb-challenged moDCs 
(Fig. 3B–D). In contrast, IL-17A and IL-10 produced by co-
cultured naive T cells showed a general trend to positively 
correlate with %CD14+ moDCs (Fig. 3B and D). Furthermore, 
induction of the Th17-specific transcription factor RORγT in 
co-cultured CD4+ naive allogenic T cells was strongly corre-
lated with the proportion of CD14+ moDCs (Fig. 3D). Mtb did 
not induce the Treg-specific transcription factor FoxP3 (data 
not shown). Collectively, the data suggest that the induction 
of CD14+ moDCs leads to reduced production of IL-12 family 
Fig. 2. Extended phenotypic analysis of Mtb-induced moDC subsets. Monocytes were harvested at day 0, immature moDCs were harvested 
at day 6, and Mtb/LPS-activated or unstimulated moDCs were harvested after 24 h of additional incubation. Subsequently, flow cytometry was 
used to assay phenotypic differences in CD14+ and CD14-neg subsets. (A and B) Division of subsets based on expression of CD14 and CD16. 
The numbers in each gate represents the frequency inside the specified gate. Error bars represent standard deviation, and data were tested for 
statistical significance using an ANOVA with Bonferroni post-hoc test (n = 8), *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Fig. 3. The effect of Mtb-induced CD14 expression on DC and naive CD4+ T-cell cytokine production. MoDCs were cultured for 24 h (A) or 6 h 
followed by a 6-day co-culture with allogenic CD4+CD45RA++ sorted T cells (B–D). Supernatants from DCs and T cells were assayed by ELISA 
(A and B), and CD14 expression on moDCs as well as intracellular cytokine production by PMA/ionomycin re-stimulated T cells was assayed 
by flow cytometry. Expression of the Th17-specific transcription factor RORγT was determined by intracellular flow cytometry. (A and B) The 
percentage of Mtb-induced CD14+ moDCs were correlated to DC (A) or T-cell (B) cytokine production. Correlation analyses were performed 
using a Pearson or a Spearman correlation test (n = 7–8). Each dot in A, B and D represents one donor. (C) Display of the intracellular cytokine 
and transcription factor staining for a representative donor from each end of the range of observed levels of %CD14+ induction. The actual 
%CD14+ moDCs is displayed above each FACS plot. The numbers in each gate represent the frequency inside the specified gate. (D) Shows 
all the donors assayed as in C.
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cytokines, decreased IFN-γ levels in CD4+ T cells and induc-
tion of IL-17A-producing Th17 cells.
PGN and ManLAM partly promotes the CD14+ 
moDC subset
Mtb expresses a range of pathogen-associated molecu-
lar patterns (PAMPs), and two of the most prominent 
Mtb-associated PAMPs are PGN and ManLAM (48). Therefore, 
we wondered if one or both of these PAMPs were responsible 
for the up-regulation of CD14 in moDCs (Fig. 4). Challenge of 
moDCs with Mtb-derived PGN resulted in distribution of the 
moDCs into a CD14+ and CD14-neg population in a manner 
similar to Mtb, whereas ManLAM alone skewed the popu-
lations similarly to unstimulated moDCs (Fig. 4A). However, 
Fig. 4. Role of PGN and ManLAM in CD14+ moDC propagation. MoDCs were stimulated with Mtb-derived PGN and ManLAM alone or in combination 
for 24 h and analyzed by flow cytometry (A, B, D and E) and ELISA (C and E). (A) Representative flow cytometry plot for the division of moDCs accord-
ing to CD14 and CD16 expression patterns. The numbers in each gate represent the frequency inside the specified gate. (B) Percentage of CD14+ 
moDCs for all donors (n = 8). (C) Level of cytokines produced by PGN stimulation alone (left) or combined with ManLAM (right). (D) Representative 
histograms for ManLAM-mediated changes of surface marker expression in PGN-activated moDCs. (E) Collected ManLAM-mediated fold changes in 
PGN-induced phenotype for all assayed surface markers and cytokines ordered by increasing mean fold change. Each dot represents one donor, and 
the error bars represent standard deviation. Data were tested for statistical significance by ANOVA by Tukey’s post-hoc test. (in B), and the Student’s 
two-tailed paired t-test or the Wilcoxon matched-pairs signed-rank test (in C and E), *P < 0.05, **P < 0.01, ***P < 0.001.
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simultaneous stimulation with PGN and ManLAM induced a 
more profound increase in the overall CD14+ population in 
moDCs from most donors (Fig. 4A and B). ManLAM has pre-
viously been shown to increase IL-10 and decrease IL-12p70 
production in LPS-triggered moDCs (30, 31). Therefore, we 
speculated whether regulatory effects of ManLAM on PGN-
activated moDCs could explain the observed increase in 
CD14+ moDCs. To test this, we measured the cytokines pro-
duced by moDCs stimulated with PGN or the combination of 
PGN and ManLAM (Fig. 4C). Stimulation with ManLAM alone 
did not induce production of any cytokines above the detec-
tion level of the assays (data not shown). Using flow cytom-
etry, we concurrently investigated whether ManLAM induced 
any noticeable differences in the display of surface markers 
on PGN-activated moDCs (Fig. 4D). When ordering the dif-
ferences in cytokines and surface markers according to the 
largest effects, it was apparent that only production of the 
cytokine IL-12p70 and expression of the surface markers MR 
and DC-SIGN were consistently down-regulated by ManLAM 
(Fig. 4E). IL-1β, IL-6, IL-10, IL-23 and IL-27 were diversely 
regulated in the donor pool and no clear effect of ManLAM 
addition on production of these cytokines was observed. 
Surface display of CD40, CD86, PD-L1 and HLA-DR (Fig. 4D 
and E) was down-regulated by ManLAM addition for most 
donors. CD16 and CD14 were up-regulated for most of the 
donors, with CD14 displayed the highest average up-regula-
tion of all assayed cytokines and markers. Collectively, these 
data demonstrated that Mtb-derived PGN and ManLAM 
synergistically modify moDCs to program the Mtb-promoted 
CD14+, IL-12p70-low phenotype.
IFN-γ but neither IL-17A nor IL-22 inhibits Mtb induction of 
CD14+ Mtb-challenged moDCs
γδT cells, naturally present as intra-epithelial lymphocytes, 
have been shown to produce the cytokines IFN-γ, IL-17A 
and IL-22 in response to Mtb challenge (49). To investigate 
their individual effect on Mtb-mediated induction of CD14+ 
moDCs, we stimulated moDCs with Mtb alone or in combina-
tion with each of these cytokines (Fig. 5). Addition of IL-17A 
or IL-22 did not affect the induction of the CD14+ moDCs 
by Mtb (Fig. 5A). Conversely, IFN-γ administration completely 
inhibited the expansion of CD14+ moDCs by Mtb, resulting 
in a DC phenotype similar to that induced by LPS (Fig. 5A 
and B). IFN-γ added as a single stimulus also inhibited the 
incubation-induced generation of intermediate CD14 expres-
sion seen for unstimulated moDCs. IL-17A and IL-22 did not 
modify the cytokine production from Mtb-activated moDCs, 
while IFN-γ modulated the production of most of the cytokines 
assayed (although only significantly for IL-10 and IL-12p70) 
(Fig.  5C and E). Most remarkably was the substantial 
increase in IL-12p70 production by IFN-γ addition, and also 
the production of IL-23 and IL-27 was consistently increased 
in all donors. IL-6 showed a slight, though insignificant, up-
regulation in most donors, while IL-1β showed no persistent 
regulation. IL-10 production was significantly inhibited upon 
addition of IFN-γ. Regarding surface marker expression, addi-
tion of IFN-γ resulted in an extensive down-regulation of CD14 
and a more modest down-regulation of CD16, indicating an 
IFN-γ-mediated reversal of the Mtb-induced propagation of 
monocyte markers on moDCs (Fig. 5D and E). MR was not 
modulated by IFN-γ, while HLA-DR, PD-L1 DC-SIGN, CD40 
and CD86 were all increased upon IFN-γ addition. Of note, 
IFN-γ alone did not have any effect on CD16, MR, HLA-DR or 
DC-SIGN, while PD-L1, CD40 and CD86 were up-regulated 
intermediately compared with the LPS- or Mtb-stimulated 
moDCs (Fig. 5D). None of the assayed markers were modu-
lated by IL-17A or IL-22 (data not shown), suggesting that 
Mtb-activated moDCs respond to exogenous IFN-γ, and not 
to IL-17A and IL-22.
Discussion
Various subpopulations of DCs are known to co-exist in 
human lungs and may arise based on different progenitors, 
and the plastic regulation of phenotypes upon exposure to 
tissue-derived factors and infectious agents (50–53). Recent 
reports suggest that some of these DCs are derived from 
monocytes (54, 55), suggesting an in vivo relevance for 
moDCs in response to lung infections such as Mtb. However, 
CD14+ DCs have not been reported in the lungs, which may 
be due to technical issues such as CD14 not being assayed 
or gated away in a lineage cocktail (50–53). Mtb stimulation of 
moDCs in vitro has been reported by others to induce close 
to no IL-12p70 (28, 38–40), and it has been suggested that 
exogenous IFN-γ is needed for moDCs to produce IL-12p70 
in response to Mtb (28). The present data elucidate the basis 
for the low level of IL-12p70 in Mtb-activated moDCs by dem-
onstrating that mainly CD14-neg moDCs induce IL-12p70 
secretion, and moreover that the presence of a CD14+ sub-
set keeps IL-12p70 low. Furthermore, we found that PAMPs 
from Mtb regulate the plasticity of moDCs toward expansion 
of a CD14+ subset and low level of IL-12p70, also repressing 
propagation of IFN-γ-producing CD4+ T-cells while promoting 
IL-17A-producing RORγT+ CD4+ T cells (Th17). Intriguingly, 
this phenotypic shift in Mtb-challenged moDCs was observed 
to be fully reversed by IFN-γ treatment, therefore suggesting 
that the role for IFN-γ in boosting IL-12p70 is partly via inhibi-
tion of DC differentiation toward a CD14+ phenotype.
We observed that Mtb-derived PGN and ManLAM in com-
bination propagated immature moDCs to expand a CD14+ 
subset analogous to that observed after Mtb treatment. It is 
therefore possible that other micro-organisms expressing 
identical or similar PAMPs can induce immune modulations 
similarly to Mtb. In contrast to stimulation by PGN + ManLAM 
or Mtb, our data show that the prototypic IL-12p70-inducing 
stimulus LPS leads to further down-regulation of CD14 com-
pared with immature moDCs. An explanation for the down-
regulation of CD14 by LPS could be due to internalization of 
the TLR4/MD-2/CD14 receptor complex upon ligand binding. 
However, as we observed that IFN-γ also mediated a down-
regulation of surface CD14, a more likely mechanism is that 
CD14 is shedded upon endogenous enzymatic activity, as 
has been demonstrated for monocytes stimulated with LPS 
or IFN-γ (56). It has been speculated that the physiological 
role of CD14 shedding is to generate soluble CD14 needed 
for CD14-neg leukocytes to respond to LPS (57). The role of 
CD14 shedding or down-regulation of surface CD14 in the 
IL-12p70-producing moDC subset could also be to limit a 
propagating immune response, as DCs induced to produce 
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Fig. 5. Role of IL-17A, IL-22 and IFN-γ in the induction of CD14+ moDCs. MoDCs were stimulated with Mtb and/or recombinant IL-17A, IL-22 
or IFN-γ at 100 ng ml−1 for 24 h and analyzed by flow cytometry (A, B, D and E) and ELISA (C and E). (A) Representative flow cytometry plot of 
CD14 and CD16 expression patterns of moDCs. The numbers in each gate represent the frequency inside the specified gate. (B) Percentage of 
CD14+ moDCs for all donors (n = 8). (C) Level of cytokines produced by CD1a+ moDCs after stimulation with Mtb alone or in combination with 
recombinant IL-17A, IL-22 or IFN-γ. Significance is based on comparison with stimulation with Mtb alone, and non-significant differences are 
not displayed. (D) Representative histograms for IFN-γ-mediated changes in Mtb-induced moDC phenotype. (E) Collected IFN-γ-mediated fold 
changes in Mtb-induced moDC phenotype for all assayed surface markers and cytokines ordered by increasing mean fold change. Each dot 
represents one donor, and the error bars display the standard deviation. Data were tested for statistical significance by Tukey’s post-hoc test (in 
B), a Kruskal–Wallis test with a Dunn’s post-hoc test (in C), and the Student’s two-tailed paired t-test or the Wilcoxon matched-pairs signed-rank 
test (in E), *P < 0.05, **P < 0.01, ***P < 0.001.
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IL-12p70 would not need to sense additional LPS. In this 
sense it is important to recognize that MD-2, CD14 and 
TLR4 all cooperate in activation of TLR4. Furthermore, Mtb-
stimulated moDCs may also up-regulate CD14 to be sensi-
tized for TLR4-triggered apoptosis, as has been described 
for murine terminally differentiated DCs (58).
In addition to the connection between surface CD14 and 
IL-12p70 production, the present data suggest that there is 
an association between CD40 expression and IL-12p70 pro-
duction. Three points of evidence supports this notion: (i) 
LPS-activated moDCs release copious amounts of IL-12p70 
and highly express CD40 compared with Mtb-activated 
moDCs, (ii) ManLAM inhibits both CD40 and IL-12p70 pro-
duction in PGN-activated moDCs and (iii) IFN-γ boosts both 
CD40 expression levels and IL-12p70 production by moDCs. 
Since CD40 is a key co-stimulatory molecule during antigen 
presentation, this could indicate that moDCs that produce 
high levels of IL-12 family cytokine are more prone to have 
strong interactions with naive T cells, as has been demon-
strated in a murine model system (59). The combined lack 
of IL-12p70 and reduced CD40 expression in moDCs stimu-
lated with Mtb could indicate that Mtb possesses an ability to 
prime the immune system away from an expansion of Th1 and 
CD8+ T cells, which represent the adequate immune pheno-
type for clearance of Mtb from infected macrophages. This 
phenomenon may be causative for the inadequate removal 
of Mtb within lungs of infected individuals, but this hypothesis 
will require adequate in situ justification in future studies.
Collectively, the observed Mtb-induced phenotype in 
moDCs could indicate a minimal Th1 induction during early 
infection phases, if in the absence of IFN-γ. However, the pul-
monary environment may influence how DCs respond to Mtb, 
as γδT cells potentially present at the site of infection could 
produce IFN-γ in response to Mtb (49). To our knowledge, the 
presence of γδT cells in the lungs at steady state has not been 
demonstrated in humans, while in macaques, small numbers 
of γδT cells have been found in the bronchoalveolar lavage 
fluid 2 weeks after BCG vaccination (60). However, if cells 
that mediate IFN-γ priming are not present in the lung dur-
ing the initiation of the Mtb infection, or if they do not interact 
with the relevant DC subsets, this important priming signal for 
expansion of IL-12p70-producing DCs, and hence early Th1 
development, could be absent. Depending on other environ-
mental cues, the γδT cells may also produce IL-17A or IL-22 
instead of IFN-γ and thereby not induce IL-12p70 production 
in DCs. However, even though IL-17A and IL-22 do not affect 
the differentiation of Mtb-stimulated moDCs alone, the com-
bination, or if present together with IFN-γ, could potentially 
modulate the DC phenotype. It will be interesting in future 
studies to assay this hypothesis. Apart from γδT cells, Th1 and 
Th17 cells can also produce these cytokines; however, due to 
an activation and expansion-based delay in the CD4+ T-cell 
immune response after Mtb infection (1), these cells will not 
affect DC differentiation upon initial encounter with Mtb.
Even though one-third of the world’s population is infected 
with Mtb, certain individuals may be able to develop an early 
Th1 response, and therefore clear the infection. Obviously, 
there are no data available about whether this is actually 
happening in humans. However, it could be speculated that 
if this was possible, it would be in the type of donor that is 
not able to up-regulate CD14 on DCs in response to Mtb (2 
out of 10 donors assayed in this study). Furthermore, it could 
be speculated that donors developing active disease are 
the type of donors with the highest CD14 up-regulation on 
DCs in response to Mtb. It would be very interesting, in future 
studies, to compare CD14 expression on moDCs from Mtb-
infected individuals that do and do not develop active TB.
In summary, Mtb holds the capacity to promote CD14+ 
subset generation in human moDCs and reduce overall 
IL-12p70 production needed for Th1 priming. This Mtb pro-
moted a DC phenotype was fully reversed by exogenously 
administered IFN-γ. Due to the observed ability of IFN-γ to 
regulate the phenotype of Mtb-exposed moDC, strategies for 
improving local IFN-γ production in tuberculosis granulomas 
could represent a way to improve Mtb clearance in latently 
infected patients.
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